2021 Year in Review: Non–Small-Cell Lung Cancer
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Patients who take immune checkpoint inhibitors experience a small number of severe side effects, although the majority of them recover with treatment.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Sotorasib and adagrasib show promising clinical activity against KRASG12C mutations in patients with NSCLC, giving new hope for patients with the previously regarded “undruggable” disease.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
A subgroup analysis of the CodeBreaK 100 trial results found that sotorasib achieved a positive response in pretreated patients with KRASG12C mutation–positive NSCLC subtypes.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
A recently released retrospective study demonstrates that NSAID use in patients with NSCLC enhances immune checkpoint efficacy.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Differences in tumor immune microenvironment, including immune cells infiltrated in tumors and PD-L1 expression, show links to the divergent response to immune checkpoint inhibitors in patients with KRAS mutation and STK11 co-mutation.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Despite apparent therapeutic efficacy and guideline recommendations, predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with NSCLC have not been widely implemented in the community oncology setting.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
According to the findings of a new trial, an investigational therapy for a second-line NSCLC treatment was found to be well-tolerated and active against KRAS mutations.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
The development of targeted therapies in cancer treatment is a key factor in improving patient care. Overcoming many current challenges will be crucial in improving access to precision medicine.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Mental burden is the number 1 impact on patients with lung cancer QOL, followed by the physical effects of their disease and treatment, whereas caregivers are more concerned with their patients’ QOL than their patients’ lung cancer stage.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Patients receiving chronic ICI therapy with any chronic lung disease, including NSCLC, should undergo pre- and posttreatment testing to ensure timely interventions for any signs of pneumonitis. Corticosteroid therapy or ICI withdrawal should be initiated immediately to aid in prompt patient recovery.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512